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Abstract 
Eating disorders are complex heritable traits influenced by both genetic and environmental 
factors. Given the progress of genomic discovery in anorexia nervosa, with the identification of 
the first genome-wide significant locus, as well as animated discussion of epigenetic mechanisms 
in linking environmental factors with disease onset, our goal was to conduct a systematic review 
of the current body of evidence on epigenetic factors in eating disorders to inform future 
directions in this area. Following PRISMA guidelines, two independent authors conducted a 
search within PubMed and Web of Science and identified 18 journal articles and conference 
abstracts addressing anorexia nervosa (n = 13), bulimia nervosa (n = 6), and binge-eating 
disorder (n = 1), published between January 2003 and October 2017. We reviewed all articles 
and included a critical discussion of field-specific methodological considerations. The majority 
of epigenetic analyses of eating disorders investigated methylation at candidate genes (n = 12), 
studying anorexia and bulimia nervosa in very small samples with considerable sample overlap 
across published studies. Three studies used microarray-based technologies to examine DNA 
methylation across the genome of anorexia nervosa and binge-eating disorder patients. Overall, 
results were inconclusive and were primarily exploratory in nature. The field of epigenetics in 
eating disorders remains in its infancy. We encourage the scientific community to apply 
methodologically sound approaches using genome-wide designs including epigenome-wide 
association studies (EWAS) as well as broaden the focus to include studies of all eating disorder 
types. 
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1 INTRODUCTION 
Eating disorders are serious illnesses associated with significantly reduced health-related quality 
of life [1,2]. Our current understanding of their etiology is piecemeal and the evidence base for 
their treatment is inadequate [3]. Over the past two decades, family, twin, and adoption studies 
have robustly shown that eating disorders are complex traits influenced by both genetic and 
environmental factors. Twin-based heritabilities for anorexia nervosa (AN) range from 48% to 
74%, for bulimia nervosa (BN) from 55% to 62%, and for binge-eating disorder (BED) from 
39% to 45% [4]. A genome-wide association study of AN has yielded the first genome-wide 
significant locus on chromosome 12—a chromosomal region previously associated with 
autoimmune diseases including type 1 diabetes [5]. AN, furthermore, shows significant genetic 
correlations with various psychiatric, personality, and metabolic phenotypes, including 
schizophrenia, neuroticism, glucose, and lipid metabolism. This panel of findings has 
encouraged a reconceptualization of AN as both a metabolic and psychiatric disorder [6]. We 
anticipate an accelerated discovery trajectory of common genetic variation in AN and extensions 
to BN and BED are underway by members of the Eating Disorders Working Group of the 
Psychiatric Genomics Consortium (http://pgc.unc.edu). This foundational work sets the stage for 
a systematic review of another branch of genetic research, namely, epigenetics. 
The genetic variants contributing to the majority of disease liability in eating disorders have yet 
to be identified, and non-genetic factors should continue to be explored—indeed monozygotic 
twins who are discordant for eating disorders have been reported, suggesting that genes do not 
act alone in eating disorders risk [7,8]. Other important and poorly understood features are the 
uneven sex distribution of eating disorders [9], and the peak age of onset (especially in AN and 
BN) hovering around adolescence and puberty [10], a period characterized by considerable 
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hormonal transformation, leading to widespread epigenetic and gene expression changes [11], 
and considerable social and emotional change [12,13]. The extreme dietary insults experienced 
by individuals with eating disorders (i.e., prolonged restriction, or intermittent binge eating and 
fasting) also have the potential to cause both temporary and longer lasting epigenetic changes, 
which may be important in treatment response and relapse. 
Complementing genetic studies of eating disorders, epigenetic mechanisms have spurred much 
interest in recent years, offering an added layer of gene regulatory information, which could link 
external and internal environmental stimuli as well as non-coding genetic variation with 
transcriptional consequences, altering downstream phenotypes. Together with an increasing 
understanding of the genetic variants underlying heritable disease risk in eating disorders, 
epigenetics has the potential to aid in disentangling the molecular genetic pathways that 
contribute to the development and progression of the illnesses. 
In the context of this review, epigenetics refers to various biochemical mechanisms giving rise to 
changes in gene regulation, which are either heritable or characterized by long-term stability 
[14]. Effectively, this means that epigenetic mechanisms regulate gene expression, and that the 
regulatory features could be copied and transmitted at cell division or could exhibit relative 
stability in the cellular environment [15]. For example, pluripotent stem cells can develop into a 
variety of different cell-types which are characterized by vastly different gene-expression 
profiles. But as cells progress further along the differentiation cascade (a process largely driven 
by epigenetic mechanisms), their gene-expression and epigenetic profiles become ever more 
stable or “locked in” [16]. While historically defined as occurring independent of the DNA 
sequence, recent work has provided evidence for widespread effects of genetic variants on 
epigenetic states. In particular, methylation quantitative trait loci (mQTLs) are increasingly being 
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characterized: single nucleotide polymorphisms (SNPs) that exert influence on the methylation 
state of a CpG site, usually in close vicinity to the SNP [17,18]. At the same time, epigenetic 
marks have been shown to be responsive to several environmental stimuli. Perhaps most 
strikingly this has been shown for tobacco smoking, which was found to have considerable 
effects on DNA methylation across several genomic regions [19]. Similarly, epigenetic profiles 
are highly correlated with chronological ageing and a strikingly accurate predictor of age has 
been derived based on the DNA methylation profiles of only around 300 CpG sites [20]. 
Biologically, epigenetic mechanisms can be categorized into three groups: DNA modifications, 
histone modifications, and non-coding RNA (Figure 1). 
DNA modifications are chemical modifications that bind to the DNA itself. Most prominently 
and prevalently, this occurs in the form of DNA methylation, the addition of a methyl-group to 
cytosine, in the context of cytosine-guanine dinucleotides (CpG sites). DNA methylation is the 
best studied epigenetic mechanism in the context of complex diseases thus far and disease-
associated methylomic dysregulation has been reported for a number of psychiatric disorders, 
including schizophrenia [21,22], Alzheimer’s disease [23,24] and autism spectrum disorder 
[25,26]. In addition to DNA methylation, its oxidized derivatives constitute further DNA 
modifications, with DNA hydroxymethylation generating increasing interest in the context of 
neuropsychiatric disease, due to its enrichment in the human brain [27,28]. 
Histone proteins constitute the cores around which DNA is wrapped in the cell nucleus. They can 
exert an effect on gene regulation by altering the accessibility of DNA sequences, primarily via 
chemical modifications to the N-terminal histone tails, which extend out of the nucleosome 
complex. An increasing number of modifications to amino acids in the histone tails are being 
identified, including methylation, acetylation, and phosphorylation. These modifications are 
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characterized by tissue-specificity and are highly correlated with different transcriptional 
chromatin states [14]. 
Finally, non-coding RNAs—expressed transcripts which do not code for proteins—have 
widespread effects on gene regulation via mechanisms including post-transcriptional silencing, 
for example by binding to transcripts and inhibiting their translation into proteins [29,30], or 
chromatin remodeling, for example by affecting the positioning of nucleosomes along the 
genome and thereby altering the accessibility of specific DNA sequences [31]. 
 
1.1 Epigenetic research in eating disorders 
Eating disorders exhibit several characteristics not in line with Mendelian inheritance, including 
sex differences (i.e., females are 8 times more likely to suffer from AN or BN than males) [9] 
and periods of increased risk of onset (i.e., particularly in adolescence and young adulthood) 
[10], as well as reported discordance between monozygotic twins [7,8]. These epidemiological 
characteristics make them an excellent target for the examination of epigenetic effects on 
appetite regulation and eating behavior. Epigenetic research in eating disorders has so far 
focused exclusively on DNA methylation, using three different approaches to investigate 
disease-associated methylomic variation. First, early DNA methylation studies measured global 
methylation levels in eating disorder cases comparing them with methylation levels in healthy 
controls. Second, DNA methylation at selected candidate genes has been assessed. These 
candidate gene studies rely on previously established links between a gene and the phenotype, 
for example from proteomic investigations or previous insights into biological pathways 
involved in a phenotype. The third approach encompasses all methods allowing for genome-wide 
coverage of DNA methylation profiles and does not rely on any prior hypotheses about the 
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nature of possible associations. In general, hypothesis-free approaches that explore the whole 
genome are the gold standard in genetic research. Genome-wide approaches are applied in the 
investigation of common genetic variation (i.e., single nucleotide polymorphisms, SNPs) in 
genome-wide association studies (GWAS) as well as in the examination of epigenetic alterations 
in epigenome-wide association studies (EWAS). EWAS refers to the site- or region-specific 
investigation of epigenetic profiles at a genome-wide level. While technically only whole-
genome next generation sequencing-based approaches cover the majority of the human genome, 
array-based technologies are also labelled as genome-wide, due to coverage of loci mapping to 
most genes and genomic regions across the genome. Most often, EWAS investigate phenotype-
associated variation in DNA methylation in a site-specific manner using microarrays, laboratory 
tools that allow researchers to study the methylation profile of thousands of CpG sites across the 
human genome simultaneously. Statistically, EWAS share similarities with GWAS in that site-
specific associations with a phenotype across a large number of genomic loci are conducted. 
However, unlike the genome sequence, epigenetic marks are dynamic and can vary across cell- 
and tissue-types, age and development, and are subject to environmental confounders including 
smoking, medication, and stress (Figure 2). 
In this sense they are more accurately characterized as intermediate biological phenotypes and 
are susceptible to confounding and other problems faced in traditional observational studies. This 
phenotypic nature of epigenetic profiles means that sources of variation or confounding need to 
be taken into account in the experimental design and statistical analyses [32,33]. For example, if 
all individuals in the control group are older than the affected individuals, an EWAS may detect 
epigenetic differences relating to ageing between the two groups, rather than differences 
associated with disease status.  
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2 METHOD 
2.1 Search strategy 
Our systematic literature review was conducted according to the PRISMA guidelines [34]. We 
conducted an exhaustive literature search using the electronic databases PubMed and Web of 
Science with a time limitation starting with articles published after 01.01.2003. We used 
following key search terms including (anorexia OR bulimia OR “binge-eating disorder” OR 
“eating disorder”) AND (epigenetics OR methylation OR histone OR “non-coding RNA”). The 
search was repeated by the co-primary author to avoid selection bias. Furthermore, we screened 
the references of published articles and reviews. Our search results including the selection 
process are presented in Figure 3 according to PRISMA guidelines. 
 
2.2 Selection criteria 
Our inclusion criteria were as follows: 
a. Studies investigating humans only 
b. Any age group 
c. Clinical diagnoses of AN, BN, or BED 
d. Investigation of any type of epigenetic mechanism: methylation, histone modification, 
non-coding RNAs 
e. Published after 01.01.2003 
f. Study includes a control group or comparison group 
g. Publications in any language 
 
 
9 
2.3 Data extraction 
We extracted following information from every identified study: 
a. Author 
b. Publication year 
c. Sample 
d. Follow-up period 
e. Diagnostic criteria 
f. Participant screening and exclusion criteria 
g. Number of cases (AN, BN, BED) 
h. Number of controls 
i. Matching of cases and controls 
j. Outcome variables (Genome-wide methylation level, candidate genes, number of CpG 
sites) 
k. Covariates 
l. Tissue 
m. Correction for multiple comparison 
n. Laboratory methods 
o. Limitations 
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3 RESULTS 
A total of 178 papers were identified by our search terms. We excluded 67 studies because they 
did not cover eating disorders, six did not investigate humans, 19 were reviews, one was a book 
chapter, and three did not examine epigenetic mechanisms. This resulted in 16 published studies 
and two conference abstracts on epigenetics that met criteria for inclusion in our systematic 
review (Figure 3). One full-text article was a duplicate of a conference abstract, resulting in 17 
studies. To our knowledge these represent all published studies and conference abstracts 
investigating epigenetics in eating disorders that were available at the close of our search in 
October, 2017. We contacted authors of conference abstracts for additional information on their 
studies (Table 1).  
[Insert Table here] 
 
3.1 Recent body of evidence 
To date, 17 studies on the epigenetics of eating disorders have been published of which four 
investigated global DNA methylation levels, 12 investigated candidate genes, and three used 
microarray-based technologies to profile DNA methylation across the human genome. All 
studies but one were cross-sectional. All studies focused exclusively on DNA methylation and 
some also investigated expression levels, but did not investigate other epigenetic mechanisms, 
such as histone modification or non-coding RNAs. The studies show extensive sample overlap as 
four studies are part of the homocysteine and DNA methylation in eating disorders (HEaD) study 
[35–38], two studies recruited inpatients at the Universitätsmedizin Charité Berlin, Germany 
[39,40], and four studies recruited at the Douglas Institute Eating Disorders Program in 
Montreal, Canada, [41–44]. 
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3.2 Global DNA methylation levels 
Four studies investigated global DNA methylation differences in eating disorders. All studies 
focused on AN [38,44–46], with one study also investigating BN [38]. Two studies reported 
global hypomethylation in individuals with AN [38,46], one study reported global 
hypermethylation in AN [44], and one reported no difference in global DNA methylation levels 
between AN cases and controls [45]. Patients suffering from BN showed no difference in their 
global DNA methylation levels compared with controls [38]. 
Limitations of global DNA methylation studies. Overall, these study results were inconclusive 
and did not reveal a clear and replicable global DNA methylation pattern in either AN or BN. All 
four studies were small, with the largest study profiling 32 AN cases and 24 BN cases, 
respectively, substantially limiting the power to detect effects. More generally, global levels of 
DNA methylation may not be of much relevance to epigenetic epidemiology, as they fail to 
provide information on region-specific DNA methylation, and lack the specificity to associate 
the dysregulation of biological pathways with the occurrence of a disease [47]. Even within the 
framework of global DNA methylation studies, the methods employed in these four studies limit 
the examination of DNA methylation to either promoter regions (for the approaches based on 
methylation sensitive restriction enzymes) or LINE1 elements [45], overlooking other parts of 
the genome. 
 
3.3 Candidate gene studies 
Candidate gene studies are hypothesis-driven and investigate DNA methylation in the vicinity of 
selected genes. These candidate genes are selected based on prior knowledge, for example, 
following differences in protein levels measured in clinical studies assessing patients with AN or 
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BN. Overall, 12 studies have been published profiling DNA methylation in candidate gene 
regions in the context of eating disorders, 11 of which focus on AN and BN. These eleven 
studies investigated genes relating to synaptic transmission [38], endoplasmatic reticulum stress 
response [38], fluid balance [35], the cannabinoid system [36], dopamine transmission 
[37,43,48], stress response [39,41], appetite regulation [39,42,48], serotonin transmission [48], 
and oxytocin [49]. One methylomic study of candidate genes in BED has been reported [50,51]. 
The study primarily investigated promoter methylation of SLC1A2, a gene involved in glutamate 
clearance, in bipolar disorder (BD). The authors found decreased DNA methylation in BD 
patients who also suffer from BED, compared to those that are only affected by BP. However, 
their sample of patients suffering from binge-eating behavior seems to comprise BN and BED 
cases, rendering the interpretation of the results ambiguous [50,51]. All candidate gene studies of 
eating disorders are described in detail in Table 1. 
Limitations of candidate gene studies. Across these studies, no clear differentially methylated 
candidate genes for AN, for BN, or for BED were robustly identified. Most candidate regions 
were only profiled once, and results of repeatedly measured genes did not replicate across the 
different studies, showing no clear eating disorder-associated methylomic variation across the 
selected candidate genes. In addition to non-replication, these studies were limited by small 
sample sizes: most of the study populations included on average only 30 cases with one study 
including 64 cases [42] and another 206 cases [43]. Furthermore subjects occasionally comprised 
a mixture of acutely ill and recovered patients [49] or a mixture of different eating disorders 
[50,51]. This is particularly concerning as dietary changes, weight changes, and accompanied 
alterations of hormonal levels during the recovery process can have a major effect on epigenetic 
profiles in individuals with eating disorders.  
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In epigenetics, as in genetics, a general drawback of a candidate gene approach is their 
hypothesis-driven design. Specific genes are selected for investigation based on prior knowledge, 
narrowing the investigation to only a very limited part of a large system and ignoring the 
majority of other genomic regions. Methodological shortcomings, such as the failure to correct 
for multiple comparisons, or failing to account for factors that influence DNA methylation, for 
instance diet and smoking, pose additional limitations to candidate gene studies. Further possible 
confounders are discussed below. 
 
3.4 Epigenome-wide association studies (EWAS) 
Three EWAS investigated genome-wide DNA methylation profiles in AN using the Illumina 
Infinium® HumanMethylation450 BeadChip. No genome-wide studies of DNA methylation 
have been published on other eating disorders. Booij et al. [44] reported 14 differentially 
methylated CpG sites comparing 29 AN patients with 15 normal-weight controls. These 14 
hypermethylated CpG sites were annotated to 11 genes (PRDM16, HDAC4, TNXB, FTSJD2, 
PXDNL, DLGAP2, FAM83A, NR1H3, DDX10, ARHGAP1, PIWIL1) [44]. Kesselmeier et. al [7] 
reported 51 differentially methylated CpG sites when comparing 22 AN cases with 24 lean 
individuals and 81 CpG sites when comparing AN cases with 30 individuals from a general 
population sample. They also showed that 54 of the 81 sites exhibited directionally consistent 
differential DNA methylation differences in a comparison of twins discordant for AN assessed 
by a binomial sign test. While the authors report a replication of hypermethylation previously 
reported at a CpG site annotated to TNXB [7,44], the significance level for this replication was 
only suggestive. In this study, controls recruited from the population were on average older than 
the AN patients which can confound the results as methylation patterns are age-dependent [7,20]. 
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In a conference presentation, Ramoz et al. [52] conducted the only longitudinal investigation of 
36 acutely ill AN patients of whom half remitted after one year. No significant differences in 
DNA methylation emerged between remitted AN patients and those patients who were still ill 
after a follow-up period of one year. However, the study does not include a control group [52]. 
Limitations. While EWAS report significant findings of identified differentially methylated 
CpG sites comparing patients suffering from AN with controls, they are limited by several 
experimental and methodological factors. First, the reported samples never included more than 
29 cases of AN which is are far too small to robustly detect patterns of differential methylation at 
a genome-wide scale, i.e. when conducting over 450,000 statistical tests [53]. Secondly, multiple 
testing correction was not always performed stringently, e.g., when “suggestive” significant 
results are reported or examined sites are filtered before or after analysis based on methylation 
variability. Thirdly, when studying associations between eating disorders and DNA methylation, 
potential confounding factors, including age, weight, diet, and medication need to be accounted 
for, as outlined in more detail in the discussion. As such, many of the EWAS included above 
labeled as pilot studies by the authors, provide motivation for further investigation, and are a 
springboard to launch full-scale projects with larger sample sizes and careful study setup, data 
collection, and analysis. Future studies will also require replication in independent samples and 
should adhere to stringent methodological criteria, including multiple test correction, no 
subjective filtering of CpG sites, and controlling for confounding factors. 
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4 DISCUSSION 
Short summary. The current research on epigenetics in eating disorders is limited and not yet 
sufficiently mature to draw sound conclusions. Studies investigating global DNA methylation 
levels and candidate gene studies are inconclusive and suffer from non-replication, in addition 
most candidate genes have only been examined once. The DNA methylation levels of candidate 
genes involved in dopamine signaling, which were measured repeatedly, did not replicate 
[37,43,48]. EWAS examining CpG sites at a genome-wide level have identified multiple AN-
associated differentially methylated sites, replicating a differentially methylated position at 
TNXB in one independent study [44]. However, the hypermethylation at this CpG site annotated 
to TNXB only reached suggestive significance in the replication attempt [7], failing to survive 
stringent correction for multiple comparisons. A false positive finding, therefore, cannot be ruled 
out. Nonetheless, these suggestive findings from the four published epigenome-wide studies, 
notwithstanding their small sample sizes, encourage further work. They provide motivation for 
rigorous investigation of epigenetic mechanisms in the etiology of eating disorders in much 
larger samples, because the lack of convincing evidence is most likely linked to small sample 
sizes drastically limiting power to detect differences in genome-wide epigenetic profiles. It will, 
however, be crucial to carefully design future epigenetic studies of eating disorders and adhere to 
stringent methodological standards to generate widely accepted and robust results. 
 
4.1 Future directions 
Sample size. One of the primary goals of future epigenetic investigations of eating disorders 
should be to increase sample sizes to improve the power to detect effects, even when effect sizes 
are small. Recent epigenetic studies of other psychiatric disorders and environmental exposures 
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have examined epigenetic differences in samples comprising thousands of participants and 
notably, replicated successes have been documented for a number of exposures and diseases 
including tobacco smoking [19], C-reactive protein levels in serum blood [54], and Alzheimer’s 
disease [23,24]. It is important to foster international collaborations in epigenetics to collectively 
achieve this aim. While several large consortium efforts have led to advances in characterizing 
baseline human tissue epigenomes [14,55,56], this is rarely extended to the realm of epigenetic 
epidemiology in complex diseases. Analogous to the collaborative success of the Psychiatric 
Genomics Consortium in genetic research, a concentrated international research effort could 
facilitate discovery in epigenetic epidemiology [57]. Unique challenges do exist in conducting 
large-scale collaborative epigenetic studies, however. Combining data from different groups and 
laboratories carries considerable challenges. Combining raw data (i.e., mega-analytic 
approaches) in epigenetics is problematic because technical variation in the data stemming from 
different laboratories and procedures (i.e., batch effects) has substantial impact on overall 
epigenomic profiles and can be insufficiently controlled for by post-hoc statistical or 
computational approaches [58,59]. Nonetheless, approaches in which each site generates a 
sufficiently large sample under nearly identical conditions that can later be meta-analyzed are 
feasible [33]. Alternatively, consistent sampling at different study sites including careful 
preanalytic sample collection and processing followed by analysis in a central laboratory could 
prevent many of the aforementioned technical issues. However, this approach is only feasible if 
all study sites meticulously follow the same protocol regarding tissue sampling, sample handling, 
and phenotyping of participants to control for possible confounders across study sites. This kind 
of pooling approach tends to be complicated by challenges associated with sample storage, 
transportation, and loss. 
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Statistical methods. As with any genome-wide investigation, the large number of tests 
performed requires special considerations for statistical analysis. Most importantly, it is essential 
to correct for the number of tests performed. The latest generation of DNA methylation arrays 
can simultaneously quantify epigenetic profiles at up to 850.000 CpG sites. An EWAS then tests 
for associations between a phenotype of interest and DNA methylation at each of these sites. 
Each of the 850.000 tests has a small probability of reporting a false positive association (usually 
5%). In order to keep the probability of making any false positive discovery below this 
probability threshold, the individual P value thresholds for each test need to be adjusted, 
resulting in a genome- or array-wide significance threshold. This correction for multiple testing 
can be achieved by common methods such as Bonferroni correction (dividing the P value 
threshold by the number of tests conducted) or a false discovery rate correction [60,61]. 
Tissue specificity. Given the prominent role epigenetic mechanisms play in cellular 
differentiation, genome-wide epigenetic profiles tend to differ substantially between different 
tissues and cell-types. These considerable differences match the differences in function each cell 
and tissue have to fulfil. For example, the functions of adipose tissue, such as fat storage, diverge 
widely from functions such as synaptic transmission performed by neurons in the brain. Different 
cellular functions require particular sets of proteins acting in concert (i.e., pathways) and 
epigenetic mechanisms control which genes are active in which cell-type and tissue-context. 
Interestingly, even within a single tissue like the brain, epigenetic profiles can distinguish 
functionally different regions (Davies et al., 2012) and cell-types (Lister et al., 2013, Ziller et al., 
2015). An important question of interest in epigenetic epidemiology is whether hypothesized 
disease-associated epigenetic dysregulation is tissue-specific. For example, are epigenetic 
correlates of psychiatric diseases restricted to the brain? To answer this, it would be ideal to 
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sample different tissue sites and to examine differential epigenetic profiles per tissue. In some 
disorders, including AN, for example, it is less straightforward to pinpoint the affected tissue of 
interest. AN is characterized by both psychiatric and metabolic features [6]. Therefore, one 
would ideally investigate epigenetic profiles in both brain tissue and metabolic tissues (e.g., 
adipose tissue, pancreas, liver, stomach, and the intestine). The investigation of brain in 
particular, however, poses considerable challenges and is typically only possible in postmortem 
samples, which are accompanied by further difficulties for epigenetic studies (e.g., time of death, 
cause of death, etc.). Nonetheless, carefully designed, ethical discussions of organ donations with 
patients and families are worthy of consideration. 
Surrogate tissues. Although investigation of epigenetic profiles in the disease-affected tissue is 
the gold standard in epigenetic studies, it is also valuable to examine epigenetics in surrogate 
peripheral tissues, including whole blood, epithelial cells, and saliva. First, while epigenetic 
profiles are highly tissue-specific and profiles observed in peripheral tissues are not generally 
representative of epigenetic variation in brain, specific genomic regions manifest high levels of 
epigenetic covariation [62–64]. For example, an existing online platform allows for the profiling 
of DNA methylation covariation between whole blood and multiple brain regions 
(http://epigenetics.essex.ac.uk/bloodbrain/). Second, while results emerging from epigenetic 
studies from peripheral samples might not necessarily reflect the epigenetic changes in disorder-
relevant tissues, they can still be used as potential biomarkers, and are collected more readily and 
less invasively than the affected tissue itself. Importantly, when analyzing whole blood 
epigenetic profiles, the blood cell-type composition also needs to be assessed. Blood is a 
heterogeneous organ comprised of distinct cell types, fulfilling specific tasks. For instance, in 
blood, specific cells fulfill functions such as oxygen transport, immune function, and nutrient 
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distribution. Because blood composition in patients suffering from eating disorders differs from 
controls [7], it is imperative to control for these differences in cell-type composition. If 
unaccounted for, epigenetic differences identified in an association scan could be related purely 
to differences in cellular composition rather than epigenetic dysregulation directly linked to 
disease etiology and progression. Where blood cell counts are not available, validated estimators 
of subcell proportions based on large reference panels can be used; i.e. cell-type proportions can 
accurately be estimated using microarray-based DNA methylation data [65]. 
Genome-wide integrated epigenetic studies. Many of the studies reviewed here use targeted 
sequencing approaches, which only allow the investigation of DNA methylation in limited 
genomic regions and ignore information from the rest of the genome. This may increase the 
chances for false positive reports via a publication bias of positive findings. Genome-wide 
technologies are less prone to this phenomenon and allow for the verification of previously 
reported differentially methylated sites. While only whole genome bisulfite sequencing allows 
full coverage of the entire genome, array-based approaches like Illumina’s EPIC array, allow 
widespread coverage of CpG sites in most genomic regions and can be a more cost-effective 
solution.  
All epigenetic studies of eating disorders published to date focused on DNA methylation only. A 
host of other sources of regulatory variation including other DNA modifications, histone 
modifications, and non-coding RNAs should be investigated, too. Furthermore, to better interpret 
the role of epigenetic modifications in disease, it is important to understand their interactions 
with the genetic sequence itself. Integrated analyses incorporating genotypic, epigenetic, 
transcriptomic, and detailed environmental data are beginning to emerge, elucidating the role of 
disease-associated epigenetic dysregulation in specific genetic and environmental contexts. 
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Increasingly detailed maps of genetic and (multi-)epigenetic profiles in health and disease will be 
essential to improve our understanding of the molecular biological pathways implicated in 
complex disease. 
 
4.2 Eating disorder specific considerations 
In addition to these general recommendations for improving epigenetic research in disease 
epidemiology, there are also a number of important eating disorder-specific complexities to be 
considered. 
Eating disorder specific confounders. Because epigenetic modifications are dynamic and can 
be altered by environmental influences, epigenetic association studies are subject to a wide range 
of confounders. Confounding in EWAS is comparable to classic observational epidemiological 
studies and ideally these confounders are addressed in the study design in such a way that they 
can be controlled for in the statistical analyses. For example, age, sex, diet, medication, 
micronutrients, dietary supplements, smoking, and alcohol consumption can interact with an 
individual’s epigenetic profile, obfuscating EWAS analyses (Figure 2).  
Diet. Diet represents a potentially very important confounder in epigenetic studies of eating 
disorders. A large body of evidence confirms that diet composition can have an effect on an 
individual’s epigenetic profile [66–70]. Eating and compensatory behaviors can include binge 
eating and purging behaviors, abuse of diet medication, laxatives, and diuretics altering fluid 
balance. It is important to record their typical use, as well as the frequencies and recency of use 
and, ideally, obtaining blood levels of diet medications when possible.  
Medication and supplements. Although there are few approved pharmaceutical treatments for 
eating disorders, medication is often prescribed off label. Antidepressants and atypical 
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antipsychotics are used to control accompanying symptoms observed in patients suffering from 
eating disorders [71]. Dosage and intake should be included in the analysis, ideally, blood levels 
should be measured, and statistical analyses corrected for. This strategy should also be followed 
for supplements, such as vitamins and micronutrients to capture as many factors influencing the 
epigenetic profile of a patients as possible. 
Hormone levels. A further possible confounder in epigenetic studies investigating eating 
disorders is introduced by hormone levels: Patients with eating disorders often show hormonal 
alterations, such as high cortisol and low sex hormones [72,73]. These types of hormones are 
direct ligands to so-called promoters, enhancers, and silencers and, therefore, influence gene 
expression and protein levels directly. If measured in the same samples, one could account for 
hormone levels in the statistical analyses. However, if substantial between group differences 
exist between cases and controls, disease and weight-associated epigenetic variation will remain 
convoluted. One option in addressing this issue is using a matched weight control group, 
potentially in addition to normal weight controls, in order to tease apart epigenetic correlates of 
eating disorder versus altered weight phenotypes. However, this approach may be limited 
because constitutionally thin individuals rarely have a BMI as low as patients suffering from AN. 
Life style factors. Another important consideration, when interpreting epigenetic associations of 
any complex disease are lifestyle factors, such as smoking and alcohol consumption. As 
environmental toxins, these substances can have a profound impact on the epigenome. If not 
accounted for appropriately, these factors can confound EWAS results: for example, prevalence 
differences in smoking between cases and controls have been shown to confound the association 
between DNA methylation and schizophrenia [21]. 
Causal attribution. As with every observational study design, the causal attribution of 
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epigenetic associations in eating disorders is extremely difficult. Assuming a detected epigenetic 
association with an eating disorder is real, then it could potentially have causally contributed to 
the disease; however, the epigenetic dysregulation could also arise as a consequence of the 
disease, its symptoms or even treatments, such as medication [74]; or, in a third scenario, there 
could be a third factor driving both the disease and the epigenetic alteration, which have no 
direct link between one another. One important approach to getting a better understanding of 
causality is to consider temporal factors [32,33]. A variety of chronologically variable factors 
should be taken into account, such as age of disorder onset, duration of illness, onset of 
menstrual disturbances, and duration of amenorrhea (in women). Longitudinal sampling and 
within-subject comparisons can help differentiate between sequelae of starvation or overeating 
and epigenetic factors that contribute to the liability to develop an eating disorder. In addition to 
this, methods using genetic variants as instrumental variables can improve causal inference. In 
epigenetic epidemiology, Mendelian Randomization is of particular importance, exploiting 
genetic influences on DNA methylation (mQTLs) to understand whether phenotypic associations 
of DNA methylation are indeed causal [75]. 
 
5. CONCLUSION 
Epigenetic research in eating disorders is still in its infancy, but initial results from pilot studies 
encourage further and larger-scale investigation. Much like progress in genomics, international 
collaborations are required to amass adequately powered sample sizes to draw credible 
conclusions from epigenetic investigations. Even more importantly, careful study design is of 
vital importance in epigenetics and can aid in avoiding potential pitfalls. Robust, replicable 
results from carefully designed studies have the potential to uncover the molecular biological 
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processes involved in disease onset and progression, they may help characterize gene regulatory 
effects of non-coding genetic variation, and, hopefully, give indications into disease-relevant 
biological pathways which could be addressed by therapeutic interventions. Clearly a 
considerable amount of functional work is required in follow-up of epigenetic association studies 
to better understand the gene regulatory, cellular, and organismal outcomes of epigenetic 
variation and derive potential translational implications and therapeutic avenues. Even non-
functional disease-associated epigenetic variation from peripheral tissue sources could, however, 
have useful implications as biomarkers for risk and prognosis assessment and for use in early 
diagnosis. 
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Figure captions 
 
Figure 1. Epigenetic mechanisms active in the human cell. Histone proteins compact 
chromosomal DNA in the nucleus of the cell and regulate gene expression. Designed by Vinícius 
Gaio, London, UK. 
 
Figure 2. Factors and environmental confounders influencing epigenetic profiles. 
 
Figure 3. PRISMA flow diagram of study selection 
 
Table 1. Overview of included studies. All studies used DSM-IV or -5 as diagnostic criteria. Tables includes used gene names and also 
standardized gene names according to www.genenames.org. 
Author & Year Sample Tissue Methylation Results 
   Global methylation AN BN BED 
Frieling (2007) AN: 22 
BN: 24 
CO: 30 
Whole blood  ↓ ↔  
Saffrey (2014) AN: 10 
CO: 10 
Buccal cells  ↔   
Tremolizzo (2014) AN: 32 
CO: 13 
Whole blood  ↓   
Booij (2015) AN: 29 
CO: 15 
Lymphocytes  ↑ 
 
  
Author & Year Sample Tissue Methylation Results 
   Candidate genes AN BN BED 
Frieling (2007)  AN: 22 
BN: 24 
CO: 30 
Whole blood 
 
SNCA 
HERP 
↑ 
↔ 
↔ 
↔ 
 
Frieling (2008) AN: 22 
BN: 22 
CO: 30 
Whole blood ANP 
Vasopressin 
↔ 
↔ 
↑ 
↔ 
 
Frieling (2009) AN: 20 
BN: 23 
CO: 26 
Whole blood CNR1/CB1 
CB2 
↔ 
n.a. 
 
 
  
Frieling (2010) AN: 22 
BN: 24 
CO: 30 
Whole blood SLC6A3/DAT 
DRD2 
DRD4 
↑ 
↑ 
↔ 
↑ 
↔ 
↔ 
 
Ehrlich (2010) AN: 31 
AN-Rec: 30 
CO: 30 
Whole blood POMC ↔ (AN) 
↔ (AN-Rec) 
  
Ehrlich (2012) AN: 30 
AN-Rec: 21 
Whole blood POMC ↔   
Pjetri (2010) AN: 45 
CO: 45 
Whole blood DRD2 
LEP 
BDNF 
SLC6A4 
↔ 
↔ 
↔ 
↔ 
  
Steiger (2013) BN: 32 
CO: 32 
Whole blood GR  ↔  
Groleau (2014) BN: 206 
CO: 102 
Whole blood DRD2  ↔  
Kim (2014) AN: 15 
CO: 36 
Buccal cells OXTR ↑   
Thaler (2014) BN: 64 
CO: 32 
Lymphocytes BDNF  ↑  
Veldic (2017) 
Jia (2017) 
BED/BN: 30 
CO: 32 
Blood SLC1A2  ↓ ↓ 
Author & Year Sample Tissue Methylation Results 
   EWAS AN BN BED 
Booij (2015) AN: 29 
CO: 15 
Lymphocytes NR1H4 
PXDNL 
2 CpG 
3 CpG 
  
Kesselmeier (2016) AN: 22 
CT: 24 
CO: 30 
Whole blood TNXB 
NR1H3 
CSGALNACT1 
↑ 
↓ 
SNP 
  
Ramoz (2017) AN: 18 
AN-Rec: 18 
n.a. n.s. ↔   
AN=anorexia nervosa, AN-Rec=recovered from anorexia nervosa, ANP/NPPA=natriuretic peptide A, BDNF=brain derived neurotrophic 
factor BED=binge-eating disorder, BN=bulimia nervosa, CNR1/CB1=cannabinoid receptor 1, CNR2/CB2= cannabinoid receptor 2, 
CSGALNACT1=chondroitin sulfate N-acetylgalactosaminyltransferase 1, DAT/SLC6A3=dopamine transporter, DRD2=dopamine receptor 
D2, DRD4=dopamine receptor D4, DSM=Diagnostic and Statistical Manual of Mental Disorders, EWAS=epigenome-wide association study, 
GR/NR3C1=glucocorticoid receptor, CO=controls, CT=constitutionally thin, HERP/HERPUD1=homocysteine inducible ER protein with 
ubiquitin like domain 1, Hcy=homocysteine, LEP=leptin, NR1H3: nuclear receptor subfamily 1 group H member 3, NR1H4=nuclear receptor 
subfamily 1 group H member 4, NR3C1/GR=nuclear receptor subfamily 3 group C member 1, OXTR=oxytocin receptor PBMC=peripheral 
blood mononuclear cell, POMC=proopiomelanocortin, PXDNL=peroxidasin like, SLC1A2=solute carrier family 1 member 2, 
SLC6A3/DAT=solute carrier family 6 member 3, SLC6A4=solute carrier family 6 member 4, SNCA=synuclein alpha, TNXB=tenascin XB 
 



